1984 graduated from the First Military Medical University, served as an instructor for two years, and was admitted to China Academy of Military Medical Sciences as a graduate student. Later, he stayed in the Institute of Basic Medical Sciences of the Chinese Academy of Sciences to engage in the research and development of national 863 biotechnology, was responsible for the pilot production of genetic engineering, and was promoted to associate researcher. 199 1, director of the sihuan biotechnology research office of China academy of military medical sciences. In recent 20 years, he has been assigned by his superiors to study biomedical development technology in the United States, Canada, Japan and western European countries for many times, and applied it to domestic R&D and production, presided over the pilot production and clinical experiment of GM-CSF, and obtained the first batch of national new drug certificates. The achievement of HLA monoclonal antibody won the second prize of National Science and Technology Progress Award. At the end of last century, Yu Falu, who participated in the establishment of PLA Pharmaceutical Group and served as the general manager of Sihuan Biopharmaceutical Enterprise, was responsible for R&D and production. It is the first famous brand product in China to pass the "Yufa Product Inspection Certificate" issued by the Japanese Ministry of Health and Welfare, and has won many meritorious awards from the Military Commission for its outstanding benefits. At the beginning of the new century, Professor Yang Zhigang served as the director of the Expert Committee of the Beauty Cosmetics Chamber of Commerce of the All-China Federation of Industry and Commerce, took the lead in introducing the international advanced beauty science and technology culture and business philosophy, established the human body network beauty regulation theory based on nervous system, immune system, gene system and endocrine system, and developed the first batch of bio-high-tech cosmetics in China.